Raltegravir: Difference between revisions
No edit summary |
No edit summary |
||
| Line 6: | Line 6: | ||
==Adult Dosing== | ==Adult Dosing== | ||
Recommended as part of a regimen including Tenofovir plus Emtricitabine or Lamivudine | |||
*Treatment-naive: 400 mg BID or 1200 mg daily | *Treatment-naive: 400 mg BID or 1200 mg daily | ||
*Treatment-experienced: 400 mg BID | *Treatment-experienced: 400 mg BID | ||
Revision as of 06:59, 19 March 2018
Administration
- Type: Antiretroviral, Integrase inhibitor
- Dosage Forms: 400 mg, 600 mg tablet
- Routes of Administration: PO
- Common Trade Names: Isentress
Adult Dosing
Recommended as part of a regimen including Tenofovir plus Emtricitabine or Lamivudine
- Treatment-naive: 400 mg BID or 1200 mg daily
- Treatment-experienced: 400 mg BID
Pediatric Dosing
Oral suspension (10 mg/mL): 6 mg/kg/dose BID
- Maximum dose: 100 mg/dose
Special Populations
- Pregnancy Rating: C
- Lactation risk: Unknown
Renal Dosing
- Mild to Moderate renal disease: No dosage adjustment necessary
- ESRD on HD: Dose after dialysis on dialysis days
Hepatic Dosing
No dosage adjustment necessary
Contraindications
- Allergy to class/drug
Adverse Reactions
Serious
- Stevens-Johnson Syndrome
- Anaphylaxis
- Myopathy/Rhabdomyolysis
Common
- Hepatic- increased transaminases
Pharmacology
- Half-life: 9 hours
- Metabolism: Hepatic glucuronidation
- Excretion: Renal
Mechanism of Action
- Reverse transcriptase inhibitor